In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions

被引:1
作者
David, Alexandra [1 ]
Golparian, Daniel [2 ]
Jacobsson, Susanne [2 ]
Stratton, Caleb [3 ]
Lan, Pham Thi [4 ]
Shimuta, Ken [5 ]
Sonnenberg, Pam [1 ]
Field, Nigel [1 ]
Ohnishi, Makoto [5 ]
Davies, Christopher [3 ]
Unemo, Magnus [1 ,2 ]
机构
[1] UCL, Inst Global Hlth, Fac Populat Hlth, London, England
[2] Orebro Univ, Fac Med & Hlth, WHO Collaborating Ctr Gonorrhoea & Other Sexually, Dept Lab Med Microbiol, Orebro, Sweden
[3] Univ S Alabama, Dept Biochem & Mol Biol, Alabama, AL USA
[4] Hanoi Med Univ, Natl Hosp Dermatol & Venereol, Hanoi, Vietnam
[5] Natl Inst Infect Dis, Dept Bacteriol 1, Tokyo, Japan
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
ANTIMICROBIAL RESISTANCE SURVEILLANCE; QUALITY-ASSURANCE; CEFTRIAXONE; STRAIN;
D O I
10.1093/jac/dkae217
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The novel dual-target triazaacenaphthylene, gepotidacin, recently showed promising results in its Phase III randomized controlled trial for the treatment of gonorrhoea. We investigated alterations in the gepotidacin GyrA and ParC targets in gonococci by in silico mining of publicly available global genomes (n = 33 213) and determined gepotidacin MICs in isolates with GyrA A92 alterations combined with other GyrA and/or ParC alterations. Methods: We examined gonococcal gyrA and parC alleles available at the European Nucleotide Archive. MICs were determined using the agar dilution method (gepotidacin) or Etest (four antimicrobials). Models of DNA gyrase and topoisomerase IV were obtained from AlphaFold and used to model gepotidacin in the binding site. Results: GyrA A92 alterations were identified in 0.24% of genomes: GyrA A92P/S/V + S91F + D95Y/A/N (0.208%), A92P + S91F (0.024%) and A92P (0.003%), but no A92T (previously associated with gepotidacin resistance) was found. ParC D86 alterations were found in 10.6% of genomes: ParC D86N/G (10.5%), D86N + S87I (0.051%), D86N + S88P (0.012%) and D86G + E91G (0.003%). One isolate had GyrA A92P + ParC D86N alterations, but remained susceptible to gepotidacin (MIC = 0.125 mg/L). No GyrA plus ParC alterations resulted in a gepotidacin MIC > 4 mg/L. Modelling of gepotidacin binding to GyrA A92/A92T/A92P suggested that gepotidacin resistance due to GyrA A92T might be linked to the formation of a new polar contact with DNA. Conclusions: In silico mining of 33 213 global gonococcal genomes (isolates from 1928 to 2023) showed that A92 is highly conserved in GyrA, while alterations in D86 of ParC are common. No GyrA plus ParC alterations caused gepotidacin resistance. MIC determination and genomic surveillance of potential antimicrobial resistance determinants are imperative.
引用
收藏
页码:2221 / 2226
页数:6
相关论文
共 42 条
  • [1] The CCP4 suite: integrative software for macromolecular crystallography
    Agirre, Jon
    Atanasova, Mihaela
    Bagdonas, Haroldas
    Ballard, Charles B.
    Basle, Arnaud
    Beilsten-Edmands, James
    Borges, Rafael J.
    Brown, David G.
    Burgos-Marmol, J. Javier
    Berrisford, John M.
    Bond, Paul S.
    Caballero, Iracema
    Catapano, Lucrezia
    Chojnowski, Grzegorz
    Cook, Atlanta G.
    Cowtan, Kevin D.
    Croll, Tristan I.
    Debreczeni, Judit E.
    Devenish, Nicholas E.
    Dodson, Eleanor J.
    Drevon, Tarik R.
    Emsley, Paul
    Evans, Gwyndaf
    Evans, Phil R.
    Fando, Maria
    Foadi, James
    Fuentes-Montero, Luis
    Garman, Elspeth F.
    Gerstel, Markus
    Gildea, Richard J.
    Hatti, Kaushik
    Hekkelman, Maarten L.
    Heuser, Philipp
    Hoh, Soon Wen
    Hough, Michael A.
    Jenkins, Huw T.
    Jimenez, Elisabet
    Joosten, Robbie P.
    Keegan, Ronan M.
    Keep, Nicholas
    Krissinel, Eugene B.
    Kolenko, Petr
    Kovalevskiy, Oleg
    Lamzin, Victor S.
    Lawson, David M.
    Lebedev, Andrey A.
    Leslie, Andrew G. W.
    Lohkamp, Bernhard
    Long, Fei
    Maly, Martin
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2023, 79 : 449 - 461
  • [2] Type IIA topoisomerase inhibition by a new class of antibacterial agents
    Bax, Benjamin D.
    Chan, Pan F.
    Eggleston, Drake S.
    Fosberry, Andrew
    Gentry, Daniel R.
    Gorrec, Fabrice
    Giordano, Ilaria
    Hann, Michael M.
    Hennessy, Alan
    Hibbs, Martin
    Huang, Jianzhong
    Jones, Emma
    Jones, Jo
    Brown, Kristin Koretke
    Lewis, Ceri J.
    May, Earl W.
    Saunders, Martin R.
    Singh, Onkar
    Spitzfaden, Claus E.
    Shen, Carol
    Shillings, Anthony
    Theobald, Andrew J.
    Wohlkonig, Alexandre
    Pearson, Neil D.
    Gwynn, Michael N.
    [J]. NATURE, 2010, 466 (7309) : 935 - U51
  • [3] Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022
    Day, Michaela
    Pitt, Rachel
    Mody, Nisha
    Saunders, John
    Rai, Rupa
    Nori, Achyuta
    Church, Hannah
    Mensforth, Sarah
    Corkin, Helen
    Jones, Jacqueline
    Naicker, Preneshni
    Khan, Wazirzada M.
    Glover, Rebecca Thomson
    Mortimer, Kalani
    Hylton, Chloe
    Moss, Elizabeth
    Pasvol, Thomas Joshua
    Richardson, Ania
    Sun, Suzy
    Woodford, Neil
    Mohammed, Hamish
    Sinka, Katy
    Fifer, Helen
    [J]. EUROSURVEILLANCE, 2022, 27 (46)
  • [4] Dillard Joseph P, 2011, Curr Protoc Microbiol, VChapter 4, DOI 10.1002/9780471729259.mc04a02s23
  • [5] Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018
    Eyre, David W.
    Town, Katy
    Street, Teresa
    Barker, Leanne
    Sanderson, Nicholas
    Cole, Michelle, I
    Mohammed, Hamish
    Pitt, Rachel
    Gobin, Maya
    Irish, Charles
    Gardiner, Daniel
    Sedgwick, James
    Beck, Charles
    Saunders, John
    Turbitt, Deborah
    Cook, Clare
    Phin, Nick
    Nathan, Bavithra
    Horner, Paddy
    Fifer, Helen
    [J]. EUROSURVEILLANCE, 2019, 24 (10): : 2 - 7
  • [6] Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018
    Eyre, David W.
    Sanderson, Nicholas D.
    Lord, Emily
    Regisford-Reimmer, Natasha
    Chau, Kevin
    Barker, Leanne
    Morgan, Markus
    Newnham, Robert
    Golparian, Daniel
    Unemo, Magnus
    Crook, Derrick W.
    Peto, Tim E. A.
    Hughes, Gwenda
    Cole, Michelle J.
    Fifer, Helen
    Edwards, Anne
    Andersson, Monique I.
    [J]. EUROSURVEILLANCE, 2018, 23 (27): : 2 - 7
  • [7] Farrell DJ, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02047-16, 10.1128/aac.02047-16]
  • [8] Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase
    Gibson, Elizabeth G.
    Bax, Ben
    Chan, Pan F.
    Osheroff, Neil
    [J]. ACS INFECTIOUS DISEASES, 2019, 5 (04): : 570 - 581
  • [9] Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates:: Resistance surveillance and typing by molecular methodologies
    Giles, JA
    Falconio, J
    Yuenger, JD
    Zenilman, JM
    Dan, M
    Bash, MC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (11) : 2085 - 2093
  • [10] Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study
    Golparian, Daniel
    Cole, Michelle J.
    Sanchez-Buso, Leonor
    Day, Michaela
    Jacobsson, Susanne
    Uthayakumaran, Thinushaa
    Abad, Raquel
    Bercot, Beatrice
    Caugant, Dominique A.
    Heuer, Dagmar
    Jansen, Klaus
    Pleininger, Sonja
    Stefanelli, Paola
    Aanensen, David M.
    Bluemel, Benjamin
    Unemo, Magnus
    [J]. LANCET MICROBE, 2024, 5 (05): : e478 - e488